Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Second Genome (San Francisco, CA) a commercial-stage microbial profiling company designed to enable diagnostic/prognostic signatures and target identification, closed a $5M Series A financing. Participants include Advanced Technology Ventures, Morgenthaler Ventures, Wavepoint Ventures and Seraph Group. Thanx for your patience as we catch-up.

Clinipace Worldwide (Durham, NC) a commercial-stage global digital clinical research organization specializing in strategic product and clinical development, closed a $15M Series C financing. Participants include Morgan Stanley, Hatteras Venture Partners and Brook Private Equity Advisors. The 3Q11 OnBioVC Trend Analysis Will Be Available Next Monday 31 October

Avantium (Netherlands) a commercial-stage clinical research organization focused on high-throughput R&D, closed a $36.2M Series B financing. Participants include Sofinnova Partners, Aster Capital, De Hoge Dennen, Aescap Venture, Capricorn Cleantech Fund, ING Corporate Investments and Navitas Capital. The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are still available. Reach […]

Molecular Imaging Research (Ann Arbor, MI) a commercial-stage specialty contract research organization providing small animal in vivo multi-modality imaging services, closed a $7M Series A financing. Participants include Baird Venture Partners and Arcus Ventures.

Crown Bioscience (Santa Clara, CA) a commercial-stage oncology focused clinical research organization, closed a $28.8M Series C financing. Participants include OrbiMed, Argonaut Private Equity, and CDIB Capital Investment.

BerGenBio (Norway) a commercial-stage RNAi-based drug target validation clinical research organization, closed a $1.3M Series A financing. Participants include the Sarsia Seed and Development fund.

Pharmaron Holding (Irvine, CA) a CRO focused on drug discovery, preclinical GLP toxicology and GMP chemical synthesis services, closed a $40 million Series C financing. Participants include DCM, Legend Capital and GL Capital Group.

InterMed Discovery (Germany) a CRO focused on natural product lead-discovery -based natural product lead-discovery company, closed a $9.9M Series B financing. Participants include Biotropics Malaysia.

Biopta (United Kingdom) a tissue-based contract research organization closed a $1.3M Series A financing. Participants include Braveheart Investment Group, Scottish Co-Investment Fund and TriCap.

Tigermed Consulting (China) a commercial-stage consulting company specializing in contract R&D services for new chemical entities, biological statistics, medical translation and registration services, closed a $5M Series A. Participants include Qimig Ventures.

Oncodesign (France) a CRO and provider of preclinical oncology services, closed a $4.7 million Series B financing. Participants include Vizille Capital Innovation and Avenir Enterprises.

Sai Advantium Pharma (India) an R&D support organization focused on medicinal chemistry, process chemistry, scale-up, analytical chemistry and manufacturing, closed a $20M Series A financing. Participants include MPM Capital.

Bridge Labs (Gaithersburg, MD) a pre-clinical contract research organization closed a $18M Series C financing. Participants include Granite Global Ventures.

« Previous Entries  Next Page »

to top of page...